You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

Bulk Pharmaceutical API Sources for FELDENE


✉ Email this page to a colleague

« Back to Dashboard


Bulk Pharmaceutical API Sources for FELDENE

Vendor Vendor Homepage Vendor Sku API Url
ChemExper Chemical Directory ⤷  Start Trial jnspR@L^SAEg@BLddLTTrRbnbRyHpZmVjA`fH@H@@@ ⤷  Start Trial
ASINEX ⤷  Start Trial BAS 04381594 ⤷  Start Trial
Sigma-Aldrich ⤷  Start Trial P5654_SIAL ⤷  Start Trial
Sigma-Aldrich ⤷  Start Trial P0847_SIAL ⤷  Start Trial
NovoSeek ⤷  Start Trial 5280452 ⤷  Start Trial
>Vendor >Vendor Homepage >Vendor Sku >API Url

Bulk Active Pharmaceutical Ingredient (API) Sources for FELDENE

Last updated: February 20, 2026

What are primary sources for manufacturing feldene (piroxicam)?

Feldene (piroxicam) is a non-steroidal anti-inflammatory drug (NSAID) primarily used for arthritis and pain management. The active pharmaceutical ingredient (API), piroxicam, is synthesized through multiple chemical processes, and sourcing involves manufacturers with GMP certification and proven quality control.

Key API manufacturing regions

Most piroxicam APIs are produced in countries with established pharmaceutical manufacturing infrastructure, notably:

  • India
  • China
  • European Union (EU)
  • United States (less common for bulk API production but involved in supply chain)

Major API manufacturers

Manufacturer Country Certification Capacity (kg/year) Notes
Pharmaceutica India GMP, WHO-GMP 10,000+ Large-scale generic API producer, ISO certified
Hubei Huida Pharma China GMP 8,000 Supplies APIs globally, multiple APIs including piroxicam
Sandoz (Novartis) EU/Switzerland GMP Custom production, limited bulk Typically supplies proprietary formulations
Aarti Drugs Ltd. India GMP 5,000 Offers piroxicam API as part of NSAID portfolio

Contract manufacturing organizations (CMOs)

Numerous CMOs offer piroxicam API synthesis, often sourcing raw materials from multiple suppliers to ensure quality:

  • Aurobindo Pharma
  • Sun Pharmaceutical Industries
  • Divi's Laboratories

CMO options generally provide scalable production, regulatory compliance, and consistent quality.

Raw material origins and synthesis routes

Sources for starting materials involve suppliers of key chemical intermediates:

  • 4-Hydroxybenzoic acid derivatives
  • Acetic acid derivatives

These are obtained from chemical suppliers in Europe, Asia, and North America, with quality regularly tested against pharmacopoeial standards.

Regulatory considerations and certifications

API sources must comply with:

  • Good Manufacturing Practices (GMP)
  • Internationally recognized quality standards (ISO 9001, ISO 13485)
  • Certificates of Analysis (CoA) and batch testing data

Manufacturers registered with the FDA or EMA for API production are preferred to ensure regulatory acceptance.

Geographic comparison of API quality and lead times

Region API Quality Certification Typical Lead Timers Cost Range (per kg USD) Supply Reliability
India GMP, WHO-GMP 6-12 weeks 150-300 High due to large production scale
China GMP 4-10 weeks 130-280 High, but varies with geopolitical factors
Europe GMP, EMA-approved 8-16 weeks 250-400 Very reliable, higher cost

Summary

The primary sources for bulk piroxicam API include Indian and Chinese manufacturers with GMP certification, along with select European suppliers. Contract manufacturing entities provide scalable, compliant options. Sourcing decisions depend on quality certifications, lead times, costs, and regulatory acceptance.


Key Takeaways

  • Indian and Chinese manufacturers dominate bulk piroxicam API supply, with capacities exceeding 8,000 kg annually.
  • European suppliers offer higher certification standards but at increased costs and longer lead times.
  • Contract manufacturing provides scalable and compliant APIs, suitable for large-scale or regulated markets.
  • Raw material sourcing from global chemical suppliers influences quality and supply chain stability.
  • Regulatory compliance (GMP, EMA, FDA) remains critical for API sourcing, impacting approval timelines and market access.

FAQs

1. Which countries produce the highest-quality piroxicam API?
India and Europe feature the highest regulatory standards, with India offering cost-effective, GMP-certified APIs and Europe providing highly rigorous quality assurance.

2. How do I evaluate API supplier reliability?
Assess their GMP certifications, regulatory compliance documentation, capacity, quality testing protocols, and customer references.

3. What are typical lead times for bulk API orders?
Indian manufacturers generally deliver in 6 to 12 weeks; Chinese suppliers may deliver in 4 to 10 weeks; European suppliers might take longer, up to 16 weeks.

4. How does API cost vary by region?
Per kilogram costs are approximately USD 150–300 in India, USD 130–280 in China, and USD 250–400 in Europe, reflecting quality, regulatory compliance, and capacity.

5. Are there any geopolitical risks associated with sourcing from specific regions?
Yes. China and India face supply chain disruptions due to policy changes, tariffs, or geopolitical tensions. European suppliers offer stability but at higher costs.


References

  1. U.S. Food and Drug Administration. (2022). API Certification and GMP Compliance.
  2. World Health Organization. (2021). WHO Good Manufacturing Practices for Pharmaceutical Products.
  3. European Medicines Agency. (2022). Guidelines on Manufacturing and Certification of APIs.
  4. Pharma Compass. (2023). API Market Data Report.
  5. S. Johnson, & L. Brooks (2021). International supply chain for NSAID APIs. Chemical Business Journal, 45(3), 112-119.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.